A Biotechnology Crossroads
By Becca Muir,
Science for the People
| 02. 01. 2021
Before Tina Stevens and Stuart Newman wrote Biotech Juggernaut, Newman helped Stevens fight legal action from an unexpectedly powerful adversary. Two scientists and the financer-author of Proposition 71, a 2004 California state initiative to fund stem cell medicine and promising imminent cures, wanted to prevent Stevens expressing her “false and misleading” views about the bill. Advocates said Proposition 71 would lead to miracle treatments for serious, debilitating illnesses such as Alzheimer’s, multiple sclerosis and heart disease. Using DNA from a patient and an egg donated by a healthy woman, researchers would produce embryonic stem cells that could then specialise and replace virtually any cell in the patient’s body.
But, Stevens, a bioethicist and historian, felt uneasy about the scientific and ethical claims of the proposition. She was part of a progressive wing of activists who were concerned about the serious risks posed to women who donated eggs for this research, as well as the troubling ethical implications of some of the techniques used. The type of stem cell research proposed in the proposition constituted a form of human cloning – somatic...
Related Articles
Cathy Tie seems to be good at starting businesses but not so dedicated to maintaining them. CGS, like many others, first heard of her thanks to Caiwei Chen and Antonio Regalado in MIT Technology Review, May 2025, as the partner (perhaps bride) of the notorious Chinese scientist He Jiankui, described in the headline as “China’s Frankenstein.” He prefers “Chinese Darwin.” She ran his Twitter account for a while, contributing such gems as:
Get in luddite, we’re going gene editing...
By Laura DeFrancesco, Nature Biotechnology | 03.17.2026
The first gene editors designed to fix genetic lesions in mutation-agnostic ways are poised to enter the clinic. Tessera Therapeutics and Alltrna, two Flagship Pioneering-funded companies, are gearing up to test novel genetic medicines in humans. Tessera received regulatory clearance...
By Darren Incorvaia, Fierce Biotech | 03.11.2026
A new method for safely inserting large chunks of DNA into genomes has now measured up in mice, potentially paving the way for the next generation of gene editing medicines.
The approach, which is described in a Nature paper...
By Carolyn Riley Chapman and Nirvan Bhatia, Hastings Bioethics Forum | 03.12.2026
Last year, researchers saved an infant named KJ from a life-threatening rare metabolic disorder using a customized gene editing therapy. This was the first time that an individualized gene therapy was used to treat a human patient, and it has...